[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363977-105":59,"doc-detail-363977-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","covalent-pan-tead-inhibitors-block-yap-activity-and-demonstrate-brain-penetrance-in-a-hippo-dependent-cancer-model-received-24-april-2025","Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model - Received 24 April 2025","","Covalent pan-TEAD inhibitors are presented as next-generation therapeutics targeting the TEAD lipid pocket in Hippo-driven cancers. The study reports two compounds—GNE-8025 and a brain-penetrant derivative GNE-2181—that covalently bind a conserved cysteine and suppress growth of YAP-driven tumor cells in vitro and in vivo. GNE-8025 also enhances the activity of MAPK pathway inhibitors and the KRASG12C inhibitor Divarasib. In vivo, GNE-2181 inhibits an intracranial tumor model, supporting effective brain penetrance and potent pathway disruption.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/covalent-pan-tead-inhibitors-block-yap-activity-and-demonstrate-brain-penetrance-in-a-hippo-dependent-cancer-model-received-24-april-2025/363977/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/covalent-pan-tead-inhibitors-block-yap-activity-and-demonstrate-brain-penetrance-in-a-hippo-dependent-cancer-model-received-24-april-2025/363977.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the therapeutic target in this study?","Question",{"text":112,"@type":113},"The study targets TEAD transcription factors by covalently binding the TEAD lipid pocket that controls YAP and TAZ oncogenic activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which inhibitors are reported, and what properties do they have?",{"text":117,"@type":113},"Two pan-TEAD inhibitors are presented: GNE-8025 and GNE-2181. GNE-2181 is described as brain-penetrant, while both bind the lipid pocket at a conserved cysteine.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the compounds affect tumor growth in experimental models?",{"text":121,"@type":113},"Both molecules inhibit growth of YAP-driven tumor cells in vitro and in vivo. Additionally, GNE-2181 suppresses growth of an intracranial tumor model in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363977,1790212050,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-026-74722-5](https://doi.org/10.1038/s41467-026-74722-5)  \nCovalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance ina Hippo-dependent cancer model  \nReceived: 24 April 2025  \n\n| Accepted: 5 June 2026 |\n| --- |\n| |\n| Check for updates |\n\nThijs J. Hagenbeek1,14, Jason Zbieg2,14, Russell Smith2,14, Sayantanee Paul1,14, Luca Gerosa3,14, Consuelo Torrini 4, Alissa D. Guarnaccia 1,5, Christy Ong1, Jennifer A. Lacap6, Miaoran Ning7, Nicole M. Sodir6, Marc Hafner3,  \nJulien Tremblay 3, James Hawley 3, Bryan Chan2, Vishal A. Verma 2, Ramsay E. Beveridge8, Peter L. Hsu 9, Gözde Ulas10, Lisha Wang10, Jim Nonomiya10, Shu Chen7, Victoria Pham5, Joshua Webster 11,  \nJessica Preston11, Jeff Hung11, Jeff Eastham11, Debra Dunlap11, Wendy Lee 2, Paul Beroza 2, Naema Nayyar4, Scott Martin1, Eva Lin1, Julie Weng1,  \nScott A. Foster1, Frances Shanahan1, Rina Fong9, Gladys Boenig 9,  \nPaola Di Lello 9, Marta H. Kubala9, Thomas Hunsaker6,  \nMirunalini Ravichandran6, Pablo Saenz-Lopez Larrocha6, Jeffrey Lau6, Le An12, Elizabeth Levy12, Maria N. Lorenzo13, Jennie R. Lill5, Zora D. Modrusan5,  \nYi-Chen Chen7, Xiaosai Yao3, Priscilla K. Brastianos 4, Danilo Maddalo 6,14  & Anwesha Dey1,14   \nTEAD transcription factors enable the oncogenic activity of deregulated Hippo signaling and are a promising therapeutic target in oncology. Targeting the TEAD lipid pocket is an established path to inhibit the oncogenic activities of cofactors YAP and TAZ. Here we present two pan-TEAD inhibitors, GNE-8025 and its in vivo brain-penetrant derivative GNE-2181, that covalently bind the lipid pocket at a conserved cysteine. Both small molecules show growth inhibition of YAP-driven tumor cells in vitro and in vivo. Moreover, we show that GNE-8025 increases the activity of a broad range of MAPK pathway inhibitors in vitro as well as the KRASG12C inhibitor Divarasib both in vitro and in vivo. In addition, GNE-2181 inhibits growth of an intracranial tumor model in vivo. Altogether we present a next-generation class of TEAD inhibitors representing a signiﬁcant advancement towards potent, speciﬁc, and effective Hippo-targeting cancer therapies.  \nInitially discovered in Drosophila melanogaster, the Hippo pathway is a highly conserved kinase cascade with tumor suppressive activity1–3. A primary activity of the Hippo pathway is inﬂuencing the phosphorylation status and subcellular localization of the transcriptional cofactors YAP and TAZ. When the pathway is active, upstream factors including NF2, MST1/2, and LATS1/2 function together to phosphorylate YAP and TAZ which results in their cytosolic sequestration and  \nproteasomal degradation. When the pathway is inactive (or mutated), unphosphorylatedYAP and TAZ translocate to the nucleus where they bind to TEAD transcription factors and induce transcriptional activation. Nuclear interaction with TEAD proteins enables YAP and TAZ to drive the transcription of genes involved in cellular proliferation and survival4–7. Loss of Hippo pathway regulation results in uncontrolled cellular growth and oncogenic transcriptional programs and  \nA full list of afﬁliations appears at the end of the paper. [e-mail:](e-mail: maddalo.danilo@gene.com)[ maddalo.danilo@gene.com](e-mail: maddalo.danilo@gene.com); [dey.anwesha@gene.com](dey.anwesha@gene.com)  \nfrequently arises in cancer. Deregulated Hippo signaling in cancer can occur through various mechanisms—mutation, overexpression, ampliﬁcation, epigenetic reprogramming—and has been shown to drive oncogenesis and tumor maintenance in a variety of contexts7–12. In vitro and in vivo cancer models have ﬁrmly established that loss of regulated Hippo signaling can drive tumorigenesis and metastasis13–19. Additionally, nuclear YAP/TAZ activity has been identiﬁed as a resistance mechanism to targeted therapies toward KRAS, EGFR, ALK, RAF, MEK, AR, and CDK4/620–29. Thus, inhibiting the transcriptional programs of YAP and TAZ hold tremendous ","cbCaioLSOqjqs2U1","https://ap.wps.com/l/cbCaioLSOqjqs2U1","pdf",8439488,27,"English","# Abstract/Overview\n# Hippo pathway and YAP/TAZ regulation\n# TEAD targeting via the lipid pocket\n# TEAD inhibitor modalities and rationale\n# Brain metastasis context and therapeutic opportunity","[{\"question\":\"What is the therapeutic target in this study?\",\"answer\":\"The study targets TEAD transcription factors by covalently binding the TEAD lipid pocket that controls YAP and TAZ oncogenic activity.\"},{\"question\":\"Which inhibitors are reported, and what properties do they have?\",\"answer\":\"Two pan-TEAD inhibitors are presented: GNE-8025 and GNE-2181. GNE-2181 is described as brain-penetrant, while both bind the lipid pocket at a conserved cysteine.\"},{\"question\":\"How do the compounds affect tumor growth in experimental models?\",\"answer\":\"Both molecules inhibit growth of YAP-driven tumor cells in vitro and in vivo. Additionally, GNE-2181 suppresses growth of an intracranial tumor model in vivo.\"}]","Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model - Received 24 April 2025 | PDF",1790154739,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b1af0027d5f134dbb24cc69937dff07.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a1ecdacaf3f9e746f26c87dcea5af93.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5144d0c970078f38a522110a2f979530.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39c7c83f2fd1595ba090dfd3daab7f88.webp",980,1301]